{'fraction_non_alphanumeric': 0.02106969205834684, 'fraction_numerical': 0.012965964343598054, 'mean_word_length': 5.717391304347826, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
NF‐κB2/p52 enhances androgen‐independent growth of human LNCaP cells via protection from apoptotic cell death and cell cycle arrest induced by androgen‐deprivation

Androgen‐deprivation therapy only causes a temporary regression of prostate cancer, as all tumors will eventually progress to refractory to hormonal therapy after 1–3 years of treatment. The underlying mechanisms of prostate cancer androgen refractory progression are incompletely understood. In this study, we employed in vitro as well as in vivo models to examine the role of NF‐κB2/p52 in prostate cancer growth and androgen independent progression.